Mithra Appoints Experienced Life Sciences Executive Christian Homsy* as Chairman - Seite 2
“I would also like to thank our outgoing Directors, Gaetan Servais (Noshaq SA), Amel Tounsi, An Cloet, Liesbeth Weynants, Patricia van Dijck, Erik Van Den Eynde (Tica Consult BV) and Christian Morretti (Selva Luxembourg SA) for their dedication to Mithra and their years of service. Christian Moretti guided the company with a steady hand, as Chairman, over the last year and I wish him all the best for the future, on behalf of the whole Mithra team.”
(*) permanent representative of Life Science Consulting SRL
For more information, please contact:
Mithra Pharmaceuticals SA David Horn Solomon Chief Executive Officer investorrelations@mithra.com |
Investor & media relations Chris Maggos Cohesion Bureau chris.maggos@cohesionbureau.com +41 79 367 6254 |
About Mithra
Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming Women’s Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra’s goal is to develop products offering better efficacy, safety and convenience, meeting women’s needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle, Mithra is now focusing on its second product Donesta, the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. www.mithra.com
ESTELLE, DONESTA and MYRING are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.
Important information
Lesen Sie auch
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Attachment